image
Healthcare - Medical - Instruments & Supplies - NYSE - US
$ 58.95
-3.17 %
$ 2.96 B
Market Cap
23.21
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one HAE stock under the worst case scenario is HIDDEN Compared to the current market price of 59 USD, Haemonetics Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one HAE stock under the base case scenario is HIDDEN Compared to the current market price of 59 USD, Haemonetics Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one HAE stock under the best case scenario is HIDDEN Compared to the current market price of 59 USD, Haemonetics Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HAE

image
$95.0$95.0$90.0$90.0$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
1.31 B REVENUE
12.01%
165 M OPERATING INCOME
5.67%
118 M NET INCOME
1.87%
182 M OPERATING CASH FLOW
-33.44%
-322 M INVESTING CASH FLOW
-124.21%
38.2 M FINANCING CASH FLOW
138.02%
349 M REVENUE
0.88%
59 M OPERATING INCOME
14.18%
37.5 M NET INCOME
10.83%
43.8 M OPERATING CASH FLOW
-10.36%
-17.4 M INVESTING CASH FLOW
25.66%
1.38 M FINANCING CASH FLOW
101.84%
Balance Sheet Haemonetics Corporation
image
Current Assets 769 M
Cash & Short-Term Investments 179 M
Receivables 207 M
Other Current Assets 384 M
Non-Current Assets 1.43 B
Long-Term Investments 0
PP&E 367 M
Other Non-Current Assets 1.06 B
8.14 %9.41 %17.47 %16.70 %48.28 %Total Assets$2.2b
Current Liabilities 300 M
Accounts Payable 73.4 M
Short-Term Debt 10.2 M
Other Current Liabilities 217 M
Non-Current Liabilities 935 M
Long-Term Debt 798 M
Other Non-Current Liabilities 138 M
5.94 %17.55 %64.55 %11.14 %Total Liabilities$1.2b
EFFICIENCY
Earnings Waterfall Haemonetics Corporation
image
Revenue 1.31 B
Cost Of Revenue 618 M
Gross Profit 692 M
Operating Expenses 527 M
Operating Income 165 M
Other Expenses 47.3 M
Net Income 118 M
1b1b1b1b1b1b800m800m600m600m400m400m200m200m001b(618m)692m(527m)165m(47m)118mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
52.83% GROSS MARGIN
52.83%
12.60% OPERATING MARGIN
12.60%
8.98% NET MARGIN
8.98%
12.25% ROE
12.25%
5.35% ROA
5.35%
6.70% ROIC
6.70%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Haemonetics Corporation
image
180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m00201620162017201720182018201920192020202020212021202220222023202320242024
Net Income 118 M
Depreciation & Amortization 97.2 M
Capital Expenditures -66.3 M
Stock-Based Compensation 28.3 M
Change in Working Capital -74.7 M
Others -10.6 M
Free Cash Flow 115 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Haemonetics Corporation
image
Wall Street analysts predict an average 1-year price target for HAE of $108 , with forecasts ranging from a low of $85 to a high of $120 .
HAE Lowest Price Target Wall Street Target
85 USD 44.19%
HAE Average Price Target Wall Street Target
108 USD 83.63%
HAE Highest Price Target Wall Street Target
120 USD 103.56%
Price
Max Price Target
Min Price Target
Average Price Target
12012011011010010090908080707060605050May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Haemonetics Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
592 K USD 2
9-12 MONTHS
2.87 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025 BOSTON , March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. prnewswire.com - 1 week ago
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma kallikrein inhibitor, in pediatric patients between the ages of two and 11 with hereditary angioedema (HAE). “We're proud to share that we achieved target enrollment in our KONFIDENT-KID trial a full year ahead of schedule and expanded the trial siz. businesswire.com - 2 weeks ago
Is it Apt to Retain HAE Stock in Your Portfolio for Now? Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics. zacks.com - 3 weeks ago
Haemonetics Announces Executive Leadership Updates Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer;  Roy Galvin named Executive Vice President, Chief Commercial Officer BOSTON , March 3, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced updates to its Executive Leadership team. Frank Chan, Ph.D. prnewswire.com - 1 month ago
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), highlighted safety and efficacy data of deucrictibant, which is currently being evaluated in two pivotal Phase 3 studies, following long-term dosing in the prophylactic and on-demand settings at the American Academy of Allergy, Asthma, & Immunology's Annual Scientific Meeting (AAAAI) and World Allergy Organization (WAO) Joint Congress, which was held from February 28–March 3, 2025, in San Diego, CA. globenewswire.com - 1 month ago
Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference BOSTON , Feb. 24, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 at 2:50 p.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://wsw.com/webcast/rj131/hae/1437678. prnewswire.com - 1 month ago
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients. In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Patients Aged 2 Years and Older.1 ZURICH , Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with Hereditary Angioedema (HAE).1 The additional subcutaneous administration option expands Takeda's offering in this space, showing dedication to the HAE community while providing individualized treatment options to support patients with a life-threatening disease, by helping to reduce HAE burden and improving their Quality of Life. prnewswire.com - 1 month ago
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) ANDEMBRY® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation enabling once-monthly subcutaneous administration The approval is based on the results of the international pivotal Phase 3 VANGUARD trial, which included HAE patients from Japan CSL is dedicated to improving the lives of those with HAE – a community that we have proudly supported for more than 40 years TOKYO , Feb. 20, 2025 /PRNewswire/ -- CSL Behring K.K. (Headquarters: Minato-ku, Tokyo; President and Representative Director: Izumi Yoshida) today announced that it has received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY® (garadacimab) Subcutaneous (S.C. prnewswire.com - 1 month ago
Astria Therapeutics: A High-Conviction Bet On HAE Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation. seekingalpha.com - 1 month ago
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) - ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites of the body- ANDEMBRY reinforces CSL's decades-long commitment to delivering innovative treatment modalities to the HAE community and comes with a convenient patient-centric pre-filled pen (auto-injector) enabling subcutaneous self-injection- Supported by the Phase 3 VANGUARD trial, this marks the third regulatory approval for ANDEMBRY, which was also recently approved by Australia's Therapeutic Goods Administration (TGA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in January MARBURG, Germany, Feb. 13, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ANDEMBRY® (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. ANDEMBRY inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites of the body. prnewswire.com - 1 month ago
HAE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket Haemonetics' third-quarter fiscal 2025 results reflect the positive effects of the company's long-range plan with meaningful earnings growth and margin expansion. zacks.com - 2 months ago
Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript Haemonetics Corporation (NYSE:HAE ) Q3 2025 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Olga Guyette - Vice President, Investor Relations and Treasury Christopher Simon - President and Chief Executive Officer James D'Arecca - EVP and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Financial Group Marie Thibault - BTIG David Turkaly - Citizens JMP Andrew Cooper - Raymond James Mike Matson - Needham & Company Craig Bijou - Bank of America Securities Michael Petusky - Barrington Research Larry Solow - CJS Securities Operator Good day, and welcome to the Haemonetics Third Quarter Fiscal Year 2025 Conference Call and Webcast. At this time, all participants are in a listen-only-mod. seekingalpha.com - 2 months ago
8. Profile Summary

Haemonetics Corporation HAE

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 2.96 B
Dividend Yield 0.00%
Description Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Contact 125 Summer Street, Boston, MA, 02110 https://www.haemonetics.com
IPO Date May 10, 1991
Employees 3657
Officers Ms. Michelle L. Basil J.D. Executive Vice President, General Counsel & Secretary Ms. Olga Guyette Senior Director of Investor Relations Mr. Josep Lluis Llorens Executive Vice President of Global Manufacturing & Supply Chain Ms. Farris Maryanne Maunsell Vice President, Chief Accounting Officer & Principal Accounting Officer Ms. Laurie A. Miller Senior Vice President & Chief Human Resources Officer Mr. Christopher A. Simon Chief Executive Officer, President & Director Mr. James C. D'Arecca CPA Chief Financial Officer, Executive Vice President & Financial Officer Mr. Rajeev Varma Senior Vice President of Strategy & Corporate Development Dr. Jan Hartmann M.D. Senior Vice President & Chief Medical Officer